佐力药业(300181) - 2024 Q2 - 季度业绩预告

Financial Forecast - The company forecasts a net profit attributable to shareholders between RMB 295 million and RMB 310 million for the first half of 2024, representing a year-on-year growth of 49.24% to 56.83% compared to RMB 197.66 million in the same period last year[6] - The net profit after deducting non-recurring gains and losses is expected to be between RMB 291 million and RMB 306 million, indicating a year-on-year increase of 50.23% to 57.97% from RMB 193.73 million last year[6] - The impact of non-recurring gains and losses on the company's net profit is estimated to be around RMB 3.95 million[16] Revenue Growth - The company achieved approximately 41% year-on-year growth in operating revenue during the reporting period, driven by strong sales of core products including Wuling Capsules and Lingze Tablets[16] - Sales revenue from traditional Chinese medicine (TCM) decoction pieces significantly increased due to a surge in online hospital sales in June, contributing to the overall revenue growth[16]